ANI launches generic Aggrenox

ANI Pharmaceuticals recently introduced aspirin and extended-release dipyridamole capsules, in a dosage strength of 25mg/200mg. The product is the generic of Boehringer Ingelheim’s Aggrenox.

It is indicated to reduce the risk of stroke in patients who have had transient ischemia of the brain or completed ischemic stroke due to thrombosis.

This launch represents ANI’s fifth generic product introduction in 2019.

ANI acquired the rights to launch this drug in an acquisition executed in 2018. As part of that acquisition, ANI entered into a supply agreement for aspirin and extended-release dipyridamole capsules whereby ANI receives drug product, packaged in the ANI label, starting on Oct. 1 and ending no later than March 1, 2021.

The product has a market value of approximately $80 million, according to IQVIA.